N-Phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats

G. Papanikolaou and K. Pantopoulos, Iron metabolism and toxicity, Toxicol. Appl. Pharm. 202 (2005) 199-211; DOI: 10.1016/j.taap.2004.06.021.10.1016/j.taap.2004.06.021Search in Google Scholar

E. Beutler, Iron storage disease: Facts, fiction and progress, Blood Cell. Mol. Dis. 39 (2007) 140-147; DOI: 10.1016/j.bcmd.2007.03.009.10.1016/j.bcmd.2007.03.009Search in Google Scholar

T. B. Chaston, and D. R. Richardson, Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity, Am. J. Hematol. 73 (2003) 200-210; DOI: 10.1002/ajh.10348.10.1002/ajh.10348Search in Google Scholar

H. Boukhalfa and A. L. Crumbliss, Chemical aspects of siderophore mediated iron transport, BioMetals 15 (2002) 325-339; DOI: 10.1023/A:1020218608266.10.1023/A:1020218608266Search in Google Scholar

J. Matijević-Sosa and Z. Cvetnić, Antimicrobial activity of N-phthaloylamino-hydroxamates, Acta Pharm. 55 (2005) 387-399.Search in Google Scholar

E. M. F. Muri, M. J. Nieto, R. D. Sindelar and J. S. Williamson, Hydroxamic acids as pharmacological agents, Curr. Med. Chem. 9 (2002) 1631-1653.10.2174/0929867023369402Search in Google Scholar

A. Kleeman, J. Engel, B. Kutscher and D. Reichert, Pharmaceutical Substances, Synthesis, Patents, Applications, 4^th ed., Thieme Medical Publishers, Stuttgart 2001.Search in Google Scholar

J. Matijević-Sosa and Lj. Butula, Synthesis and mitodepressive activity of some phthalimidoal-kanehydroxamic acids, Acta Pharm. 43 (1993) 185-194.Search in Google Scholar

C. A. Burtis and E. R. Ashwood, Clinical Chemistry in Original Papers for Olympus AU 640 Reagents, WB Saunders Company, Philadelphia 1994, pp. 2059-2065.Search in Google Scholar

D. A. Brown, K. M. Herlihy and S. K. O'Shea, Kinetics of iron(III) chelation from polynuclear oxo-hydroxy aggregates by hydroxamic acids: Understanding ferritin iron (III) sequestration, Inorg. Chem. 38 (1999) 3198-3202; DOI: 10.1021/ic990158o.10.1021/ic990158oSearch in Google Scholar

R. C. Hider, Z. D. Liu and S. Piyamongkol, Design and properties of 3-hydroxypyridin-4-one iron chelators with high Fe(3+) values, Transfus. Sci. 23 (2000) 201-209; DOI: 10.1016/S0955-3886(00)00090-4.10.1016/S0955-3886(00)00090-4Search in Google Scholar

E. Farkas, É. A. Enyedy and I. Fábián, New insight into the oxidation of Fe(II) by desferrioxamine B (DFB), Inorg. Chem. Commun. 6 (2003) 131-134; DOI: 10.1016/S1387-7003(02)00703-7.10.1016/S1387-7003(02)00703-7Search in Google Scholar

N. Gálvez, B. Ruiz, R. Cuesta, E. Colacio and J. M. Dominquez-Vera, Release of iron ferritin by aceto- and benzohydroxamic acids, Inorg. Chem. 44 (2005) 2706-2709; DOI: 10.1021/ic048840s.10.1021/ic048840s15819556Search in Google Scholar

M. Porcu, N. Landis, S. Salis, M. Corda, P. Orru, E. Serra, B. Usai, G. Matta and R. Galanello, Effect of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure, Eur. J. Heart Fail. 9 (2007) 320-322.10.1016/j.ejheart.2006.08.00617029959Search in Google Scholar

F. Aucella, M. Vigilante, P. Scalzulli, P. Musto, M. Prencipe, G. L. Valente, M. Carotenuto and C. Stallone, Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure, Nephrol. Dial. Transplant. 14 (1999) 1171-1175.10.1093/ndt/14.5.1171Search in Google Scholar

N. T. V. Le and D. R. Richardson, Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation, Blood 104 (2004) 2967-2975; DOI: 10.1182/blood-2004-05-1866.10.1182/blood-2004-05-1866Search in Google Scholar

D. R. Richardson and P. Ponka, Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease, J. Lab. Clin. Med. 131 (1998) 306-315; DOI: 10.1016/S0022-2143(98)90180-9.10.1016/S0022-2143(98)90180-9Search in Google Scholar